AbbVie is a leading biopharmaceutical company with a robust portfolio of drugs used to treat over 75 conditions. Known for innovation, AbbVie has replaced its blockbuster product, Humira, with newer successes like Rinvoq and Skyrizi, ensuring future growth and maintaining its status as a Dividend King.

Bristol Myers Squibb, another global biopharmaceutical company, is investing in acquisitions to prepare for the patent cliff. While facing short to medium-term earnings growth forecasts, Bristol Myers Squibb offers a safe and growing dividend with a current yield of 5.1%, having raised it for 18 consecutive years.

Danaher, a global leader in life sciences, operates through subsidiaries and has outperformed the market with its continuous improvement model. With a decade of dividend increases, Danaher’s stock offers future growth potential, as analysts estimate double-digit annual earnings growth and a rising dividend that aligns with earnings estimates.

Read more at Yahoo Finance: Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever